GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » 3-Year FCF Growth Rate

Lipocine (Lipocine) 3-Year FCF Growth Rate : 21.60% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Lipocine 3-Year FCF Growth Rate?

Lipocine's Free Cash Flow per Share for the three months ended in Mar. 2024 was $0.45.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 21.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 30.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 23.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Lipocine was 55.30% per year. The lowest was -87.60% per year. And the median was 22.50% per year.


Competitive Comparison of Lipocine's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Lipocine's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Lipocine's 3-Year FCF Growth Rate falls into.



Lipocine 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Lipocine  (NAS:LPCN) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Lipocine 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Lipocine's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipocine (Lipocine) Business Description

Traded in Other Exchanges
N/A
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107.
Executives
Mahesh V. Patel director, officer: President and CEO C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono director 18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos director C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos officer: Chief Medical Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty officer: Principal Accounting Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi director C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown officer: EVP and CFO 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink director 2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass officer: EVP and Chief Commercial Offic 3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila officer: Chief Business Officer AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran officer: CTO and VP RandD C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell officer: VP Finance C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons officer: VP Corp Business Development 837 4TH AVE, SALT LAKE CITY UT 84103